Research Article

Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation

Bin Wu,1 Jin Li,2 Houwen Lin,1 and Haixiang Wu3,4

1Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai 201114, China
2Department of Ophthalmology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
3Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
4Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, Fudan University, Shanghai 200031, China

Correspondence should be addressed to Haixiang Wu; whx577@163.com

Received 7 December 2015; Revised 29 March 2016; Accepted 30 March 2016

Academic Editor: Biju B. Thomas

Copyright © 2016 Bin Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To assess the cost-effectiveness of bevacizumab compared to ranibizumab, photodynamic therapy (PDT), and usual care for the treatment of age-related macular degeneration (AMD) in China. Methods. A Markov model was developed according to patient visual acuity (VA) in the better-seeing eye (Snellen scale). Four cohorts of patients were treated with one of the following therapies: bevacizumab, ranibizumab, PDT, or usual care. Clinical data related to treatments were obtained from published randomized clinical trials. Direct medical costs and resource utilization in the Chinese health care setting were taken into account. Health and economic outcomes were evaluated over a lifetime horizon. Sensitivity analyses were performed. Results. Treatment with ranibizumab provided the greatest gains in quality-adjusted life-years (QALYs). The cost per marginal QALY gained with bevacizumab over usual care was $1,258, $3,803, and $2,066 for the predominantly classic, minimally classic, and occult lesions, respectively. One-way sensitivity analysis showed considerably influential factors, such as utility values and effectiveness data. Probabilistic sensitivity analysis indicated that, compared to usual care, PDT and ranibizumab most cases would be cost-effective in the bevacizumab arm at a threshold of $7,480/QALY. Conclusion. Bevacizumab can be a cost-effective option for the treatment of AMD in the Chinese setting.

1. Introduction

Age-related macular degeneration (AMD) is a progressive chronic macular disease of the central retina that leads to vision loss and significant functional impairment worldwide [1]. In the white population aged 40 years and older, the prevalence of early and late AMD is nearly 6.8% and 1.5%, respectively [2]. The age-specific prevalence of late AMD in Asians was largely similar to that in white people [3]. Age is one of the main risk factors for AMD; according to a report by the World Health Organization (WHO), the estimated number of cases will double by 2020 due to trends in the growth of aging populations [4]. In China, the prevalence of AMD in the early 1990s was nearly 5%, and over the last decade, the prevalence has increased nearly twofold in the aging population. At present, blindness caused by AMD has become one of the most important health challenges in China [5].

Most visual loss occurs in the late stages of AMD in one of two forms: geographic atrophy (“late dry”) or neovascular (“wet”) AMD. Although only an estimated 10%–15% of all AMD cases take the neovascular form, it is responsible for more than 80% of severe visual loss (visual acuity of 20/200 or worse) due to choroidal neovascularization, which results in hemorrhage and fluid leakage and fibrosis [6]. Based on the pattern of lesions, wet AMD can be classified into three subtypes: occult (35%–73% of patients), minimally classic (35%), and predominantly classic (20%–44%) [7–9]. Several biological mechanisms are thought to be involved in the pathogenesis of AMD, particularly vascular endothelial growth factor (VEGF). VEGF is a key regulator of angiogenesis, and overexpression can block vascular growth and neovascular
regression [10]. In last decade, new agents targeted against VEGF, such as bevacizumab (Avastin, Genentech/Roche) and ranibizumab (Lucentis, Genentech/Novartis), have substantially changed the patterns of therapies for wet AMD. They have been shown to be superior to conventional treatments (e.g., photodynamic therapy [PDT]) in improving visual acuity gain and preventing visual acuity loss in patients with wet AMD [5, 6, 11–15].

These new agents have improved clinical outcomes as well as reducing the human and socioeconomic consequences of AMD. Visual impairment can result in substantial functional loss, reduced quality of life, and increased risk of comorbidities, such as depression and falls, which can increase the socioeconomic burden on patients and societies [16–18]. Evidence from US medical claims data shows that the total annual direct cost of AMD is $575–733 million dollars [10]. In Western Europe, the yearly budgetary impact of AMD in 2002 was from €51.3 to €101.1 million [19]. There are a number of published economic analyses comparing different therapies for AMD, including laser photocoagulation, verteporfin with PDT, pegaptanib, bevacizumab, and ranibizumab, which show that these therapies have improved health outcomes and reduced resource consumption associated with visual impairment [20]. However, no published studies have investigated the cost-effectiveness of these therapies in a health resource-limited setting.

Verteporfin and ranibizumab have been licensed for AMD treatment in China. However, these agents are not covered by medical insurance. The higher cost of these two agents has limited their widespread use in Chinese clinical practice. At present, bevacizumab has also been approved to treat cancers. However, its similar efficacy and much lower cost than ranibizumab have stimulated the off-label use of bevacizumab for wet AMD [5]. The objective of this study was to evaluate the cost-effectiveness of bevacizumab, ranibizumab, and verteporfin with PDT versus usual care for the predominantly classic, minimally classic, and occult AMD populations. The usual care in the current analysis is the supportive care based on Chinese ophthalmologist's opinion, which would annually include two outpatients' visit for an ophthalmologist with one optical coherence tomography. The perspective of the Chinese health care system, representative of a health resource-limited setting, was adopted in this analysis, and only direct costs were considered.

2. Methods

2.1. Model Overview. A Markov model was used to simulate the lifetime disease course of wet AMD for a cohort of patients. The model structure is shown in Figure 1, including the death state and the five health states based on the Snellen chart of visual acuity (SCVA) in the better-seeing eye as follows: SCVA $>20/40$, 20/40 to $>20/80$, 20/80 to $>20/200$, 20/200 to $>20/400$, and $\leq 20/400$ (light perception only). Transitions between the health states can occur every 3 months according to specified probabilities. After each cycle, the SCVA could remain in the current state, improve by at least 3 lines, or worsen by 3 to 6 lines and $>6$ lines. Patients could transition to the death state from any health state in the model. The R statistical environment (version 3.2.2; R Development Core Team, Vienna, Austria) was used to develop and solve the model.

The baseline characteristics of the hypothetical cohorts are based on a previously published study [21]. All patients were newly diagnosed with wet AMD and the starting age for treatment at the base case was 73.6 years. Due to a lack of China-specific data, the initial SCVA was derived from a previously published study based on a Chinese patient cohort [22]. Patients would receive one of four of the following treatments: bevacizumab, ranibizumab, PDT with verteporfin, or usual care. In the model, active treatments were assumed to take up to 2 years.

The cost and health outcome were measured for each treatment in patients with wet AMD; the quality-adjusted life-year (QALY) gained was used as the primary health outcome. A cost-utility analysis was conducted and the incremental cost-effectiveness ratio (ICER) was estimated by comparing two treatments. Based on a WHO recommendation, the per capita gross domestic product (GDP) of China per QALY was used as a cost-effectiveness threshold in this analysis [23–25].

In the current analysis, a yearly discount rate of 3% was applied to both costs and QALYS, which is a general approach in the Chinese setting.

2.2. Clinical Efficacy. The clinical data for each AMD treatment were taken from published clinical trials (Table 1). Based on the opinions of Chinese ophthalmologists, it was assumed that PDT was administered to all AMD patients regardless of lesion subtype for ethical reasons, although PDT is indicated in patients with predominantly classic lesions. The VIP and TAP trials reported the percentages of patients experiencing a 3-line gain, 3- to 6-line loss, and >6-line loss among patients receiving PDT with verteporfin and a placebo (usual care) at 1 and 2 years [9, 26–29]. An exponential distribution was used for the 3-month transition probabilities between health states. Thus, the 3-month transition probabilities could be calculated by the density method [30]. To extrapolate effects beyond the time horizon of the trials, estimated transition probabilities for year 2 in the usual care cohort were applied to each state of the model from year 3 until death. The MARINA trial compared the efficacy of ranibizumab to usual care in patients with minimally classic and occult lesions and the ANCHOR trial made a comparison between ranibizumab and PDT for predominantly classic lesions [11, 14]. Due to a lack of published studies directly comparing the four treatment strategies, an indirect comparison was performed using the risk ratio in cumulative probabilities between ranibizumab and PDT or usual care to project the model output. The results of the CATT trial were used to estimate the RR between bevacizumab and ranibizumab for the three types of lesions [13].

2.3. Resource Utilization and Costs. This analysis was conducted from the perspective of the Chinese health care
system. Costs are presented in 2012 US dollars ($). Direct medical costs were incorporated into the model, including costs related to AMD treatment and follow-up, direct medical costs related to AMD comorbidities, and direct nonmedical-related costs. All of the health resource unit costs were estimated using data from local health systems or the National Development and Reform Commission (NDRC) of China [31].

With regard to medical costs associated with AMD treatment, unit costs for physician consultations and diagnostic procedures were estimated from a previous study [32]. The model assumed that patients in the usual care arm would receive routine follow-up and supportive care but not active treatment. The average number of treatments with PDT in years 1 and 2 was obtained from the VISION trial, which showed that patients receiving treatment with PDT at the physician’s discretion had 2.05 and 1.54 drug administrations in years 1 and 2, respectively [12]. Ranibizumab was administered at a dosage of 0.5 mg as an outpatient procedure. The frequency of injections was eight in the first year and six in the second year, which was derived from data obtained in the ANCHOR and MARINA trials [11,14]. For bevacizumab, the administered dosage was 1.25 mg and the frequency of injections was assumed to be similar to ranibizumab per their equivalent effects on visual acuity when administered according to the same schedule [13]. The annual mean cost associated with PDT, bevacizumab, and ranibizumab treatment in these arms was measured by multiplying the average frequency of treatments per year by the percentage of patients receiving the treatment and by the average cost of treatment. Age-specific natural mortality rates were obtained from the life tables for WHO member states (2011) [33].

The unit costs of managing SAEs (e.g., endophthalmitis, traumatic injury to the lens, and retinal detachment) were estimated based on the treatment path recommended by a panel of Chinese clinical ophthalmologists. The rates of SAEs were obtained from the clinical trials (Table 2).

Low vision increases the risks of numerous comorbidities, such as depression, falls, and the need for assisted living [9,34]. The model estimated the costs associated with comorbidities for patients with varying degrees of visual acuity. The prevalence of depression in China was derived from a community-based study reported by Chen et al. [35]. The incidence of a one-time fall is nearly 18% according to the literature [36]. Based on interviews with clinical experts, the probability of receiving assisted living services was assumed to be similar to that in the report published by Earnshaw et al. [9]. Sensitivity analysis was performed to examine the impact of this assumption. The unit costs associated with comorbidities are depicted in Table 2.

2.4. Health Utilities. Due to the absence of reported Chinese-specific utility scores as to any degree of VA impairment, the utility values of the five VA states were derived from the study reported by Brown et al. using the time-tradeoff method [37] and it is assumed that they also represent local patients (Table 3). In the current analysis, only the bilateral disease
Table 1: Cumulative probability and RR of losing or gaining visual acuity.

| Parameters                  | Predominantly classic | Minimally classic | Occult with no classic |
|-----------------------------|-----------------------|-------------------|------------------------|
| **Cumulative probability of change in vision** |                       |                   |                        |
| Usual care at 1 year        |                       |                   |                        |
| Gain of >3 lines            | 2.41%                 | 1.92%             | 2.17%                  |
| Loss of 3–6 lines           | 23.10%                | 28.85%            | 22.83%                 |
| Loss of >6 lines            | 29.14%                | 16.35%            | 32.61%                 |
| Usual care at 2 years       |                       |                   |                        |
| Gain of >3 lines            | 1.48%                 | 2.89%             | 1.71%                  |
| Loss of 3–6 lines           | 6.33%                 | 6.33%             | 6.33%                  |
| Loss of >6 lines            | 4.21%                 | 10.57%            | 14.13%                 |
| PDT at 1 year               |                       |                   |                        |
| Gain of >3 lines            | 5.66%                 | 6.44%             | 3.01%                  |
| Loss of 3–6 lines           | 26.51%                | 27.23%            | 28.92%                 |
| Loss of >6 lines            | 13.46%                | 16.83%            | 22.29%                 |
| PDT at 2 years              |                       |                   |                        |
| Gain of >3 lines            | 1.75%                 | 1.98%             | 1.81%                  |
| Loss of 3–6 lines           | 6.35%                 | 5.44%             | 8.16%                  |
| Loss of >6 lines            | 3.00%                 | 2.97%             | 6.63%                  |
| RR of ranibizumab versus PDT|                       |                   |                        |
| at 1 year                   |                       |                   |                        |
| Gain of >3 lines            | 7.2                   | N/A               | N/A                    |
| Loss of 3–6 lines           | 0.1                   | N/A               | N/A                    |
| Loss of >6 lines            | 0                     | N/A               | N/A                    |
| at 2 years                  |                       |                   |                        |
| Gain of >3 lines            | 0.49                  | N/A               | N/A                    |
| Loss of 3–6 lines           | 4.35                  | N/A               | N/A                    |
| Loss of >6 lines            | 0.06                  | N/A               | N/A                    |
| RR of ranibizumab versus usual care |           |                   |                        |
| at 1 year                   |                       |                   |                        |
| Gain of >3 lines            | N/A                   | 6.69              | 6.69                   |
| Loss of 3–6 lines           | N/A                   | 0.17              | 0.17                   |
| Loss of >6 lines            | N/A                   | 0.09              | 0.09                   |
| at 2 years                  |                       |                   |                        |
| Gain of >3 lines            | N/A                   | 0.42              | 0.42                   |
| Loss of 3–6 lines           | N/A                   | 3.78              | 3.78                   |
| Loss of >6 lines            | N/A                   | 0.14              | 0.14                   |
| RR of bevacizumab versus ranibizumab |                   |                   |                        |
| at 1 and 2 years            |                       |                   |                        |
| Gain of >3 lines            | 0.92                  | 0.92              | 0.92                   |
| Loss of 3–6 lines           | 1.07                  | 1.07              | 1.07                   |
| Loss of >6 lines            | 1.07                  | 1.07              | 1.07                   |

RR: risk ratio.
N/A: not applicable.

Treatment in the better-seeing eye was evaluated because there is a more notable correlation between utility values and VA for the better-seeing eye than for the poorer-seeing eye [37].

2.5. Sensitivity Analyses. Sensitivity analyses are typically conducted to test whether a model has any structural errors (i.e., to ensure that it is robust) and to assess how outcomes are substantially affected when specific parameters are changed. One-way sensitivity analyses were conducted to examine the impact of input parameters in the model on the robustness of results over the ranges shown in Tables 1–3 or assuming ±20% of mean values. A probabilistic sensitivity analysis (second-order Monte Carlo simulation) was conducted using a cohort of 1000 simulations to simultaneously examine the
### Table 2: Direct costs* related to AMD treatment and comorbidities.

| Parameters                                | Median unit cost (range) | Average number (range) | Annual mean total cost  | Source   |
|-------------------------------------------|--------------------------|------------------------|-------------------------|----------|
| Ophthalmologist consultation              | 3.2 (0.8–47.6)           | 1 time per cycle       | 12.8                    | [32]     |
| Optical coherence tomography              | 31.7 (23.8–39.7)         | 1 time per cycle       | 126.8                   | [32]     |
| Fluorescein angiography                   | 58.7 (44–73.4)           | 2 times per year       | 234.8                   | [32]     |
| Verteporfin per 15 mg                     | 2539.7 (1904.8–374.6)*   |                        |                         | [32]     |
| Laser activation                          | 238.1 (158.7–317.5)      |                        |                         | [32]     |
| PDT (verteporfin per 15 mg + laser activation) | 2.05 (1.5375–2.5625) at 1 year | 5694.5 at 1 year       | Calculated             |
| Intravitreal injection                    | 41.3 (31–51.6)           | 1.54 (1.155–1.925) at 2 years | 4277.8 at 2 years       | Calculated |
| Ranibizumab per 0.5 mg                    | 1523.8 (1142.9–1904.8)*  | 8 (6–12) at 1 year     | 12190.4 at 1 year       | Local charge |
| Bevacizumab per 1.25 mg                   | 10.5 (7.9–13.1)*         | 8 (6–12) at 1 year     | 84 at 1 year            | Local charge |
| Adverse reactions                         |                          |                        |                         |          |
| Endophthalmitis                           |                          |                        |                         |          |
| Ranibizumab arm                           | 1.4% (1.05%–1.75%) during 1 year | 22.2                    | Local charge            |
| Bevacizumab arm                           | 2.8% (2.1%–3.5%) during 1 year | 44.4                    | Local charge            |
| Lens damage                               |                          |                        |                         |          |
| Ranibizumab arm                           | 0.4% (0.3%–0.5%) during 1 year | 6.3                     | Local charge            |
| Bevacizumab arm                           | 0.4% (0.3%–0.5%) during 1 year | 6.3                     | Local charge            |
| Retinal detachment                        |                          |                        |                         |          |
| Ranibizumab arm                           | 0.3% (0.23%–0.38%) during 1 year | 5.7                     | Local charge            |
| Bevacizumab arm                           | 0.3% (0.23%–0.38%) during 1 year | 5.7                     | Local charge            |
| Comorbidities                             |                          |                        |                         |          |
| Depression                                | 130.6 (111.2–156.4)      | 2.2% (1.65%–2.75%) during 1 year | 3                       | Local charge |
| Fall                                      | 8093.9 (364.6–1823.2)    | 18% (14.5%–28.60%) during 1 year | 23                      | Local charge |
| Assisted living                           | 432.7 (324.5–540.8)      | 2.1% (1.58%–2.63%) during 1 year | 77.9                    | Local charge |

*Costs are presented as US dollars (January 2015 exchange rate, US$ = CYN 6.30).

*The range was used for sensitivity analysis.
Table 3: Utilities for each visual acuity state.

| Visual acuity | Utility value |
|---------------|---------------|
| >20/40        | 0.89 (0.82–0.96) |
| ≤20/40 to >20/80 | 0.81 (0.73–0.89) |
| ≤20/80 to >20/200 | 0.57 (0.47–0.67) |
| ≤20/200 to >20/400 | 0.52 (0.38–0.66) |
| ≤20/400       | 0.40 (0.29–0.50) |

impact of uncertainty across all parameters. Proportions, probabilities, and utilities were subject to beta distribution, whereas cost was sampled from lognormal distribution with an assumed standard deviation of 20% from mean values. The results are shown on a cost-effectiveness plane. The outcomes projected from all 1000 simulations were used to plot acceptability curves, which estimated the willingness to pay (WTP) threshold for an incremental unit of effectiveness.

3. Results

3.1. Base-Case Analysis. In the base-case analysis (Table 4), treating AMD patients with ranibizumab, compared to the other three alternatives, provided the greatest clinical outcomes at a higher cost for all types of lesions in the lifetime horizon. In patients with predominantly classical, minimally classical, and occult types of lesions, the estimated lifetime costs for the ranibizumab arm were notably 240% higher than usual care, 61% higher than PDT, and 29% higher than bevacizumab; the respective projected marginal gains in QALYs for patients with predominantly classical, minimally classical, and occult types of lesions were 15%, 5%, and 9% for usual care; 9%, 3%, and 6% for PDT; and 2%, 1%, and 1% for bevacizumab. PDT was less cost-effective than bevacizumab and was dominated due to fewer health benefits and higher costs regardless of lesion type. The ICERs of bevacizumab over usual care ranged from $1,258 for predominantly classical to $3,803 for minimally classical, which were lower than the two other active treatment alternatives.

3.2. Sensitivity Analysis. The one-way sensitivity analyses showed that some model variables had a substantial impact on the results, which are presented in Table 5. The substantially influential variables included age, utility values, RR of bevacizumab over ranibizumab, frequency of bevacizumab injections, and the cost of bevacizumab and intravitreal injection. Other parameters, such as the cost and probability of SAEs, produced little model output sensitivity. One-way sensitivity analyses also showed that the ICERs of active treatment were more favorable in patients with VA ≤20/40 to >20/80 for all three types of lesions (Figure 2).

Pursuant to a probabilistic sensitivity analysis, acceptability curves showed that AMD treatment with bevacizumab, compared to usual care, PDT, and bevacizumab, yielded acceptable ICERs in most cases at the $7,480/QALY threshold for all patients, regardless of lesion type (Figure 3).

4. Discussion

There was great excitement among ophthalmologists and patients after clinical trials demonstrated the medical benefits of ranibizumab and bevacizumab. However, in the context of limited health care resources, the widespread use of new drugs, especially those that are more effective but more expensive than the competing alternatives, would increase the socioeconomic burden on people and societies. Thus, the economic evaluation of ranibizumab and bevacizumab in the clinical setting is urgently needed. In this light, we conducted a cost-effectiveness analysis of three active treatments for patients with AMD in the Chinese health care setting: bevacizumab, ranibizumab, and verteporfin with PDT versus usual care.

Results of the analysis indicated that the cost per QALY gained with bevacizumab therapy over usual care in a lifetime horizon was $1,258, $3,803, and $2,066 for predominantly classical, minimally classical, and occult lesions, respectively, just below the per capita GDP of China ($7,480 in 2011), which is highly cost-effective according to WHO recommendations [24, 25]. Another anti-VEGF drug, ranibizumab, yielded the greatest clinical outcomes compared to the alternatives under examination, but at a higher cost. The ICERs of ranibizumab over usual care were all greater than three times the per capita GDP of China, which indicates that ranibizumab is not a cost-effective option in the Chinese setting. Verteportin with PDT was dominated by bevacizumab due to its lower health outcomes and higher cost. This outcome, however, was affected by alternative scenarios explored in the sensitivity analyses. They corroborated calculations that showed that the administration of bevacizumab was cost-effective in nearly 95.4%, 77.6%, and 95.2% of predominantly classical, minimally classical, and occult lesion cases, respectively. In addition to a probabilistic sensitivity analysis, multiple one-way sensitivity analyses were performed to test the robustness of the model. The results of the majority of these analyses did result in the ICERS of bevacizumab exceeding the $7,480 threshold; thus, the robustness of the main analysis was further strengthened (Table 5). The time horizon of the analysis had a substantial impact on model output, partly because short time horizons could not reflect subsequent long-term health benefits.

This study is one of the few economic analyses to compare costs and health outcomes of bevacizumab, ranibizumab, and verteporfin with PDT. Our conclusion was similar to the report recently published by Patel et al. [38]. The authors evaluated the cost-effectiveness of bevacizumab relative to ranibizumab for AMD based on a four-state Markov model for 20 years. They found that the ICER for bevacizumab was dominant compared with ranibizumab. However, different types of lesions were not taken into account in their analysis; the ICER of bevacizumab was −$54,649 over ranibizumab per marginal QALY because bevacizumab yielded 3.48 more QALYs than ranibizumab, and the cost for bevacizumab treatment was $190,300 lower than ranibizumab. These findings were notably different than our results. In our analysis, treatment with ranibizumab produced more health outcomes than bevacizumab because the mean change in
visual acuity score favored treatment with ranibizumab, although no statistical analysis was detected according to the results of the CATT trial [13]. One of the potential reasons for this difference is that the study reported by Patel et al. used a different model design and did not adjust the data from varied sources before incorporating it into the model. In addition to the comparison between bevacizumab and ranibizumab, several published studies have evaluated the cost-effectiveness of ranibizumab relative to PDT and usual care [20,39,40]. These studies found that ranibizumab can be a cost-effective option in comparison with selected alternatives because the ICERs were relatively lower than the corresponding threshold recommended by their local health care systems. It should be noted that these studies were conducted with regard to developed countries, which had relatively rich health resources and a higher threshold than developing countries, such as China. To the best of our knowledge, our analysis is the first economic investigation associated with the treatment of AMD. Our findings might supply some reference information for patients, physicians, and decision-makers from developing regions.

The results of this analysis also showed that early treatment was accompanied by improved clinical outcomes at a lower cost with respect to all three types of lesions and the greatest incremental benefits were observed in the health state with VA ≤ 20/40 to > 20/80 (Figure 2). This result parallels the findings of a cost-effective analysis reported by Javitt et al., which showed that treatment with pegaptanib should be started as early as possible to maximize clinical and economic benefits [41]. In addition to the early VA health state, results from one-way sensitivity analysis found that younger patients could achieve more favorable economic outcomes in cases of predominantly classical and occult lesions (Table 3). When a patient with VA ≤ 20/40 to > 20/80 was diagnosed with AMD at 50 years old, the ICERs of bevacizumab therapy over usual care fell to $1,148 and $2,032 for predominantly classical and occult lesions, respectively; when a patient was 88 years old, the ICERs increased to $1,774 and $2,972, respectively. These findings suggest that early community screening and intervention may be attractive. Recently, a system for automated detection of early AMD signs from retinal photographs was reported, with sensitivity and specificity rates of 75% [42]. Such progress makes the early detection of AMD more feasible.

Similar to all modeling analyses, our study had several limitations that require consideration. First, the current analysis used an indirect method to evaluate the health and economic outcomes of the four treatments due to the absences of direct head-to-head studies comparing bevacizumab, ranibizumab, and verteporfin with PDT with usual care. This would lead to inevitable uncertainty in the results because the data from the varied studies had a high degree of heterogeneity, given the different study designs, patient cohorts, and dosing schedules. To examine the robustness of the model, sensitivity analyses were conducted by varying model parameters. Future analyses should be performed if the data from head-to-head trials become available. Second, due to the unavailability of Chinese-specific data, especially efficacy and utility data, the current analysis used data mainly obtained from literature published abroad, which would produce a degree of uncertainty with respect to Chinese data, pursuant to the hypothesis that foreign observations are similar to those in a Chinese setting. However, one recent study showed that the efficacy of bevacizumab outcomes compared favorably to a Chinese population, which would result in the underestimation of the cost-effectiveness of bevacizumab [5]; moreover, as suggested by some Chinese ophthalmologists, the quality of life of AMD patients in China should not be significantly different from that of external AMD patients. Although efficacy and utilities had some impact on our results, the results of the sensitivity analysis indicated that their influence was limited. Third, we did not examine the “continuous treatment effect” approach under which active treatments, especially the bevacizumab and ranibizumab treatments, would be administered beyond the trial time frames because the efficacy of continuous treatment

| Treatment arms                  | Costs ($) | Vision-years | QALYs | ICER versus usual care | Comments     |
|--------------------------------|-----------|--------------|-------|------------------------|--------------|
| Predominantly classic          |           |              |       |                        |              |
| Usual care                     | 8,618.5   | 2.38         | 3.97  | 44,333                 | Dominated    |
| PDT                            | 18,292.5  | 3.23         | 4.19  | 36,089                 | Not cost-effective |
| Ranibizumab                    | 29,468.3  | 4.16         | 4.55  |                        |              |
| Bevacizumab                    | 9,232.8   | 3.92         | 4.46  | 1,258                  | Cost-effective |
| Minimally classic              |           |              |       |                        |              |
| Usual care                     | 8,663.5   | 2.80         | 4.10  |                        |              |
| PDT                            | 18,289.1  | 3.11         | 4.19  | 102,828                | Not cost-effective |
| Ranibizumab                    | 29,480.0  | 3.77         | 4.31  |                        |              |
| Bevacizumab                    | 9,242.8   | 3.59         | 4.26  | 3,803                  | Cost-effective |
| Occult with no classic         |           |              |       |                        |              |
| Usual care                     | 8,594.9   | 2.08         | 3.90  |                        |              |
| PDT                            | 18,240.1  | 2.43         | 4.01  | 91,424                 | Dominated    |
| Ranibizumab                    | 29,465.1  | 3.61         | 4.26  | 58,790                 | Not cost-effective |
| Bevacizumab                    | 9,227.8   | 3.44         | 4.21  | 2,066                  | Cost-effective |
| Parameters                          | Predominantly | Minimally | Occult |
|------------------------------------|---------------|-----------|--------|
| **Age**                            |               |           |        |
| 55                                 | 1,148         | 11,278    | 2,032  |
| 88                                 | 1,774         | 4,368     | 2,972  |
| **RR (bevacizumab versus ranibizumab)** |               |           |        |
| Gain of >3 lines at 1 year          |               |           |        |
| Base – 20%                         | 1,604         | 4,700     | 2,308  |
| Base + 20%                         | 1,023         | 3,183     | 1,883  |
| Loss of 3–6 lines at 1 year        |               |           |        |
| Base – 20%                         | 1,256         | 3,677     | 2,052  |
| Base + 20%                         | 1,272         | 3,937     | 2,101  |
| Loss of >6 lines at 1 year         |               |           |        |
| Base – 20%                         | 1,263         | 3,579     | 1,982  |
| Base + 20%                         | 1,265         | 4,052     | 2,177  |
| Gain of >3 lines at 2 years        |               |           |        |
| Base – 20%                         | 1,264         | 3,802     | 2,076  |
| Base + 20%                         | 1,264         | 3,802     | 2,076  |
| Loss of 3–6 lines at 2 years       |               |           |        |
| Base – 20%                         | 975           | 2,142     | 1,572  |
| Base + 20%                         | 1,708         | 12,922    | 2,921  |
| Loss of >6 lines at 2 years        |               |           |        |
| Base – 20%                         | 1,264         | 3,802     | 2,076  |
| Base + 20%                         | 1,264         | 3,802     | 2,076  |
| **Utility**                        |               |           |        |
| >20/40                             |               |           |        |
| 0.82                               | 1,296         | 3,841     | 2,088  |
| 0.96                               | 1,234         | 3,763     | 2,064  |
| ≤20/40 to >20/80                   |               |           |        |
| 0.73                               | 1,477         | 4,364     | 2,271  |
| 0.89                               | 1,104         | 3,368     | 1,912  |
| ≤20/80 to >20/200                  |               |           |        |
| 0.47                               | 1,405         | 5,762     | 3,088  |
| 0.67                               | 1,149         | 2,837     | 1,563  |
| ≤20/200 to >20/400                 |               |           |        |
| 0.38                               | 1,155         | 2,791     | 1,984  |
| 0.66                               | 1,396         | 5,961     | 2,177  |
| ≤20/400                            |               |           |        |
| 0.29                               | 993           | 2,963     | 1,430  |
| 0.5                                | 1,681         | 5,118     | 3,523  |
| **Cost ($)**                       |               |           |        |
| Bevacizumab per 1.25 mg            |               |           |        |
| 7.9                                | 1,191         | 3,571     | 1,960  |
| 13.1                               | 1,336         | 4,033     | 2,191  |
| Intravitreal injection             |               |           |        |
| 31                                 | 1,102         | 3,287     | 1,818  |
| 51.6                               | 1,426         | 4,317     | 2,334  |
| **Frequency of bevacizumab injections at 1 year** |               |           |        |
| 6                                  | 1,221         | 3,666     | 2,008  |
| 12                                 | 1,349         | 4,074     | 2,212  |
| **Frequency of bevacizumab injections at 2 years** |               |           |        |
| 4.5                                | 1,234         | 3,707     | 2,029  |
| 12                                 | 1,383         | 4,181     | 2,266  |
| **Time horizon**                   |               |           |        |
| 2 years                            | 3,935         | 8,498     | 7,227  |
| 10 years                           | 1,277         | 3,353     | 2,064  |
beyond 2 years is still unclear. Fourth, this study excluded indirect costs, such as the loss of productivity, which may have resulted in a substantial social economic burden for a patient’s family and society. If these indirect costs were considered, this analysis would have underestimated the cost-effectiveness of active treatment, which would become more cost-effective because indirect costs would be decreased by active treatments. Finally, to simplify the model, utility decrements for adverse events were not taken into account because the adverse events of bevacizumab, ranibizumab, and verteporfin with PDT were both mild and infrequent; this had little impact on the outcomes as depicted by Brown et al. [43]. Nevertheless, we are confident that the model faithfully represented the common clinical conditions of AMD in a health resource-limited setting. We believe that this study has the potential to be an important reference point for decision-makers.

In conclusion, although bevacizumab is not licensed for the treatment of AMD in China, bevacizumab is highly cost-effective compared with ranibizumab and verteporfin with

---

**Figure 2:** Sensitivity analysis of the effects of the initial health states. Values are indicated (y-axis) as cost per additional quality-adjusted life-year (QALY) gained.
PDT because of the more favorable ICER in the Chinese health care setting. To reduce the financial burden related to AMD, we suggest that the government license off-label use of bevacizumab and set strict rules for avoiding sterile endophthalmitis [44, 45]. Early intervention would improve the cost-effectiveness of active treatments.

 Disclosure

The funding agency had no role in the study design, data collection and analysis, decision to publish, or preparation of the paper.

Competing Interests

The authors declare no competing interests.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (nos. 71373160 and 81300781) and the Fourth Round of Three-Year Action Plan on Public Health Discipline and Talent Program (Evidence-Based Public Health and Health Economics, no. 15GWZK0901).
References

[1] L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, “Age-related macular degeneration,” The Lancet, vol. 379, no. 9827, pp. 1728–1738, 2012.

[2] W. Smith, J. Assink, R. Klein et al., “Risk factors for age-related macular degeneration: pooled findings from three continents,” Ophthalmology, vol. 108, no. 4, pp. 697–704, 2001.

[3] A. Laude, P. D. Cackett, E. N. Vithana et al., “Polypoidal choroidal vasculopathy and age-related macular degeneration: same or different disease?” Progress in Retinal and Eye Research, vol. 29, no. 1, pp. 19–29, 2010.

[4] World Health Organization, Vision 2020, and International Agency for the Prevention of Blindness, Global Initiative for the Elimination of Avoidable Blindness: Action Plan 2006–2011, http://www.who.int/blindness/Vision2020%20-report.pdf.

[5] X. Li, Y. Hu, X. Sun, J. Zhang, and M. Zhang, “Bevacizumab for neovascular age-related macular degeneration in China,” Ophthalmology, vol. 119, no. 10, pp. 2087–2093, 2012.

[6] R. D. Jager, W. F. Mielers, and J. W. Miller, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2606–2617, 2008.

[7] T. W. Olsen, X. Feng, T. J. Kasper, P. P. Rath, and E. R. Steuer, “Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration,” Ophthalmology, vol. 111, no. 2, pp. 250–255, 2004.

[8] C. Zawinka, E. Ergun, and M. Stur, “Prevalence of patients presenting with neovascular age-related macular degeneration in an urban population,” Retina, vol. 25, no. 3, pp. 324–331, 2005.

[9] S. R. Earnshaw, Y. Moride, and S. Rochon, “Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada,” Clinical Therapeutics, vol. 29, no. 9, pp. 2096–204, 2007.

[10] S. Kondo, M. Asano, and H. Suzuki, “Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by three antibody,” Biochemical and Biophysical Research Communications, vol. 194, no. 3, pp. 1234–1241, 1993.

[11] D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006.

[12] E. S. Gragoudas, A. P. Adams, E. T. Cunningham Jr., M. Feinsod, and D. R. Gayer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004.

[13] D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011.

[14] P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006.

[15] A. Tufail, P. J. Patel, C. Egan et al., “Bevacizumab for neovascular age-related macular degeneration (ABC Trial): multicentre randomised double masked study,” The British Medical Journal, vol. 340, Article ID c2459, 2010.

[16] R. J. Casten, B. W. Kovner, and W. Tasman, “Age-related macular degeneration and depression: a review of recent research,” Current Opinion in Ophthalmology, vol. 15, no. 3, pp. 181–183, 2004.

[17] M. M. Brown, G. C. Brown, J. D. Stein, Z. Roth, J. Campanella, and G. R. Beauchamp, “Age-related macular degeneration: economic burden and value-based medicine analysis,” Canadian Journal of Ophthalmology, vol. 40, no. 3, pp. 277–287, 2005.

[18] A. Cruess, G. Zlateva, X. Xu, and S. Rochon, “Burden of illness of neovascular age-related macular degeneration in Canada,” Canadian Journal of Ophthalmology, vol. 42, no. 6, pp. 836–843, 2007.

[19] J. Bonastre, C. Le Pen, P. Anderson, A. Ganz, P. Berto, and G. Berdeau, “The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom,” The European Journal of Health Economics, vol. 3, no. 2, pp. 94–102, 2002.

[20] P. Mitchell, L. Annemans, R. White, M. Gallagher, and S. Thomas, “Cost effectiveness of treatments for wet age-related macular degeneration,” PharmacoEconomics, vol. 29, no. 2, pp. 107–131, 2011.

[21] C. Youxin, G. E. Jian, Y. A. Ni Mi et al., “Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients,” Chinese Journal of Ophthalmology, vol. 43, no. 3, pp. 198–205, 2007.

[22] W.-M. Chan, T. Y. Y. Lai, A. L. Wong, J.-P. Tong, D. T. L. Liu, and D. S. C. Lam, “Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 337–341, 2006.

[23] World Development Indicators of China, October 2015, http://data.worldbank.org.cn/country/china.

[24] H.-G. Eichler, S. X. Kong, W. C. Gerth, P. Mavros, and B. Jönsson, “Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?” Value in Health, vol. 7, no. 5, pp. 518–528, 2004.

[25] C. J. L. Murray, D. B. Evans, A. Acharya, and R. M. P. M. Baltussen, “Development of WHO guidelines on generalized cost-effectiveness analysis,” Health Economics, vol. 9, no. 3, pp. 235–251, 2000.

[26] Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, “Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report,” Archives of Ophthalmology, vol. 117, no. 10, pp. 1329–1345, 1999.

[27] N. M. Bressler, J. Arnold, M. Benchabonne et al., “Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes—TAP report no. 3,” Archives of Ophthalmology, vol. 120, no. 11, pp. 1443–1454, 2002.

[28] J. Arnold, I. Barbazetto, R. Birngruber et al., “Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2,” Archives of Ophthalmology, vol. 119, no. 2, pp. 198–207, 2001.

[29] Verteporfin in Photodynamic Therapy Study Group, “Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin.
in photodynamic therapy report 2,” *American Journal of Ophthalmology*, vol. 131, no. 5, pp. 541–560, 2001.

[30] D. K. Miller and S. M. Homan, ”Determining transition probabilities: confusion and suggestions,” *Medical Decision Making*, vol. 14, no. 1, pp. 52–58, 1994.

[31] ”National Development and Reform Commission (NDRC),” July 2012, http://en.ndrc.gov.cn/.

[32] X. Zong, Y. Xie, S. M. Wu, L. Zhu, and L. H. Sun, ”Economic analysis of verteporfin photodynamic therapy for the treatment of age-related macular degeneration,” *China Journal of Pharmaceutical Economics*, vol. 15, pp. 11–21, 2010.

[33] ”Life tables for WHO Member States,” July 2015, http://www.who.int/gho/countries/chn/en/.

[34] J. C. Javitt, Z. Zhou, and R. J. Willke, ”Association between vision loss and higher medical care costs in medicare beneficiaries costs are greater for those with progressive vision loss,” *Ophthalmology*, vol. 114, no. 2, pp. 238–245, 2007.

[35] R. Chen, Z. Hu, X. Qin, X. Xu, and J. R. M. Copeland, ”A community-based study of depression in older people in Hefei, China-the GMS-AGECAT prevalence, case validation and socio-economic correlates,” *International Journal of Geriatric Psychiatry*, vol. 19, no. 5, pp. 407–413, 2004.

[36] J. T. Wang, Z. Chen, and Y. T. Song, ”Falls in aged people of the Chinese mainland: epidemiology, risk factors and clinical strategies,” *Aging Research Reviews*, vol. 9, pp. S13–S17, 2010.

[37] G. C. Brown, S. Sharma, M. M. Brown, and J. Kistler, ”Utility values and age-related macular degeneration,” *Archives of Ophthalmology*, vol. 118, no. 1, pp. 47–51, 2000.

[38] J. J. Patel, M. A. S. Mendes, M. Bounthavong, M. L. D. Christopher, D. Boggie, and A. P. Morreale, ”Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model,” *Journal of Evaluation in Clinical Practice*, vol. 18, no. 2, pp. 247–255, 2012.

[39] J. L. Colquitt, J. Jones, S. C. Tan, A. Takeda, A. J. Clegg, and A. Price, ”Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation,” *Health Technology Assessment*, vol. 12, no. 16, pp. 3–201, 2008.

[40] K. Athanasakis, V. Fragoulakis, V. Tsiantou, P. Masaoutis, N. Maniadakis, and J. Kyriopoulou, ”Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece,” *Clinical Therapeutics*, vol. 34, no. 2, pp. 446–456, 2012.

[41] J. C. Javitt, G. P. Zlateva, S. R. Earnshaw et al., ”Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity,” *Value in Health*, vol. 11, no. 4, pp. 563–574, 2008.

[42] G. Quellec, S. R. Russell, J. M. Seddon et al., ”Automated discovery and quantification of image-based complex phenotypes: a twin study of drusen phenotypes in age-related macular degeneration,” *Investigative Ophthalmology & Visual Science*, vol. 52, no. 12, pp. 9195–9206, 2011.

[43] G. C. Brown, M. M. Brown, J. Campanella, and G. R. Beauchamp, ”The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration—a value-based reappraisal with 5-year data,” *American Journal of Ophthalmology*, vol. 140, no. 4, pp. 679.e1–679.e10, 2005.

[44] H.-B. Huang, Y. Pan, and T. Liu, ”Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China,” *Clinical and Experimental Optometry*, vol. 96, no. 1, pp. 106–108, 2013.

[45] X. Sun, X. Xu, and X. Zhang, ”Counterfeit bevacizumab and endophthalmitis,” *The New England Journal of Medicine*, vol. 365, no. 4, pp. 378–379, 2011.